Clinical Trial Update: Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies [Phase 2]

View source ↗

Summary

Open-label extension study for rheumatoid arthritis patients completing a Phase 2 trial of R935788; the study was terminated and results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• R935788

Snippet

Sponsor: AstraZeneca | Conditions: Rheumatoid Arthritis | Phase 2 | Status: TERMINATED | Results posted: 2014-06-25